Demographics, baseline disease characteristics, and prior treatment history
| . | Daratumumab plus pom-dex (N = 103) . |
|---|---|
| Age, median (range), y | 64.0 (35-86) |
| <65 | 52 (51) |
| 65 to <75 | 43 (42) |
| ≥75 | 8 (8) |
| Sex | |
| Male | 57 (55) |
| Female | 46 (45) |
| Race | |
| White | 79 (77) |
| Other | 24 (23) |
| ECOG performance status | |
| 0 | 28 (27) |
| 1 | 63 (61) |
| 2 | 12 (12) |
| >2 | 0 (0) |
| Type of myeloma | |
| IgG | 63 (61) |
| IgA | 18 (18) |
| IgD | 2 (2) |
| Light chain | 20 (19) |
| Time since initial diagnosis (y), median (range) | 5.1 (0.4-16.0) |
| Number of prior lines, median (range) | 4.0 (1-13) |
| Prior lines of therapy | |
| 1* | 3 (3) |
| 2 | 22 (21) |
| 3 | 25 (24) |
| >3 | 53 (52) |
| Prior ASCT | 76 (74) |
| Prior therapy | |
| PI + IMiD | 102 (99) |
| PI | 102 (99) |
| BORT | 101 (98) |
| CARF | 34 (33) |
| IXA | 2 (2) |
| LEN | 103 (100) |
| THAL | 29 (28) |
| BORT + LEN | 101 (98) |
| BORT + LEN + CARF | 34 (33) |
| Steroids | 103 (100) |
| Chemotherapy | 103 (100) |
| Refractory to | |
| PI only | 9 (9) |
| IMiD only | 21 (20) |
| PI + IMiD | 73 (71) |
| Cytogenetic abnormality† | |
| Standard risk | 65 (75) |
| High risk‡ | 22 (25) |
| del17p | 16 (18) |
| t(4;14) | 6 (7) |
| t(14;16) | 1 (1) |
| . | Daratumumab plus pom-dex (N = 103) . |
|---|---|
| Age, median (range), y | 64.0 (35-86) |
| <65 | 52 (51) |
| 65 to <75 | 43 (42) |
| ≥75 | 8 (8) |
| Sex | |
| Male | 57 (55) |
| Female | 46 (45) |
| Race | |
| White | 79 (77) |
| Other | 24 (23) |
| ECOG performance status | |
| 0 | 28 (27) |
| 1 | 63 (61) |
| 2 | 12 (12) |
| >2 | 0 (0) |
| Type of myeloma | |
| IgG | 63 (61) |
| IgA | 18 (18) |
| IgD | 2 (2) |
| Light chain | 20 (19) |
| Time since initial diagnosis (y), median (range) | 5.1 (0.4-16.0) |
| Number of prior lines, median (range) | 4.0 (1-13) |
| Prior lines of therapy | |
| 1* | 3 (3) |
| 2 | 22 (21) |
| 3 | 25 (24) |
| >3 | 53 (52) |
| Prior ASCT | 76 (74) |
| Prior therapy | |
| PI + IMiD | 102 (99) |
| PI | 102 (99) |
| BORT | 101 (98) |
| CARF | 34 (33) |
| IXA | 2 (2) |
| LEN | 103 (100) |
| THAL | 29 (28) |
| BORT + LEN | 101 (98) |
| BORT + LEN + CARF | 34 (33) |
| Steroids | 103 (100) |
| Chemotherapy | 103 (100) |
| Refractory to | |
| PI only | 9 (9) |
| IMiD only | 21 (20) |
| PI + IMiD | 73 (71) |
| Cytogenetic abnormality† | |
| Standard risk | 65 (75) |
| High risk‡ | 22 (25) |
| del17p | 16 (18) |
| t(4;14) | 6 (7) |
| t(14;16) | 1 (1) |
Values represent n (%) of patients unless otherwise indicated. Total percentages within categories may not equal 100% due to rounding.
ASCT, autologous stem cell transplantation; BORT, bortezomib; CARF, carfilzomib; ECOG, Eastern Cooperative Oncology Group; IXA, ixazomib; LEN, lenalidomide; THAL, thalidomide.
Three patients were identified by investigators as having ≥2 prior lines of therapy, but, per IMWG criteria, they were later determined to have received only 1 prior line that included both bortezomib and lenalidomide.
N = 87.
The presence of high-risk cytogenetic abnormalities was adjudicated locally per individual center practices.